{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:40:03Z","timestamp":1792014003655,"version":"4.4.0"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.25584","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T15:39:26Z","timestamp":1632497966000},"page":"e2125584","source":"Crossref","is-referenced-by-count":32,"title":["Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency"],"prefix":"10.1001","volume":"4","author":[{"given":"Peter A.","family":"Ljubenkov","sequence":"first","affiliation":[{"name":"Memory and Aging Center, Department of Neurology, University of California at San Francisco, Weill Institute for Neurosciences, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Edwards","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, Department of Neurology, University of California at San Francisco, Weill Institute for Neurosciences, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Iaccarino","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, Department of Neurology, University of California at San Francisco, Weill Institute for Neurosciences, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"La Joie","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, Department of Neurology, University of California at San Francisco, Weill Institute for Neurosciences, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C.","family":"Rojas","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, Department of Neurology, University of California at San Francisco, Weill Institute for Neurosciences, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Koestler","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, Department of Neurology, University of California at San Francisco, Weill Institute for Neurosciences, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baruch","family":"Harris","sequence":"additional","affiliation":[{"name":"ROME Therapeutics, Cambridge, Massachusetts"},{"name":"Metera Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley F.","family":"Boeve","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Borroni","sequence":"additional","affiliation":[{"name":"Neurology Unit, Centre for Neurodegenerative Disorders, ASST Spedali Civili Brescia, Italy"},{"name":"Department of Clinical and Experimental Sciences, University of Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"van Swieten","sequence":"additional","affiliation":[{"name":"Department of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray","family":"Grossman","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Pasquier","sequence":"additional","affiliation":[{"name":"Lille University, Inserm 1172, CHU Lille, CNR-MAJ, DISTALZ, LiCEND, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni B.","family":"Frisoni","sequence":"additional","affiliation":[{"name":"Lab of Alzheimer's Neuroimaging and Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J.","family":"Mummery","sequence":"additional","affiliation":[{"name":"Dementia Research Centre, Institute of Neurology, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Vandenberghe","sequence":"additional","affiliation":[{"name":"Neurology Service University Hospitals Leuven, Leuven, Belgium"},{"name":"Laboratory for Cognitive Neurology, Department of Neurosciences, Leuven Brain Institute, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Le Ber","sequence":"additional","affiliation":[{"name":"Paris Brain Institute, Sorbonne University, Paris, France"},{"name":"Neurology Department, Reference Centre for Rare or Early Dementias, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Hannequin","sequence":"additional","affiliation":[{"name":"CHU Rouen Normandie, Service de Neurologie, Rouen University Hospital, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"McGinnis","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital, Charlestown"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Auriacombe","sequence":"additional","affiliation":[{"name":"Neurology Department, CHU Bordeaux, Bordeaux Hospital, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Onofrj","sequence":"additional","affiliation":[{"name":"Department of Neuroscience Imaging, University G d'Annunzio of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira J.","family":"Goodman","sequence":"additional","affiliation":[{"name":"Compass Research, Bioclinica, Orlando, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry J.","family":"Riordan","sequence":"additional","affiliation":[{"name":"Worldwide Clinical Trials, King of Prussia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Wisniewski","sequence":"additional","affiliation":[{"name":"Invicro, A Konica Minolta Company, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Hesterman","sequence":"additional","affiliation":[{"name":"Institute for Neurodegenerative Disorders, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Marek","sequence":"additional","affiliation":[{"name":"Invicro, A Konica Minolta Company, Boston, Massachusetts"},{"name":"Institute for Neurodegenerative Disorders, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth Ann","family":"Haynes","sequence":"additional","affiliation":[{"name":"FORUM Pharmaceuticals Incorporated, Waltham, Massachusetts"},{"name":"Alector, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Patzke","sequence":"additional","affiliation":[{"name":"Voyager Therapeutics, Watertown, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Koenig","sequence":"additional","affiliation":[{"name":"FORUM Pharmaceuticals Incorporated, Waltham, Massachusetts"},{"name":"Arkuda Therapeutics, Watertown, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Hilt","sequence":"additional","affiliation":[{"name":"Arkuda Therapeutics, Watertown, Massachusetts"},{"name":"Lysosomal Therapeutics, Cambridge, Massachusetts"},{"name":"Frequency Therapeutics, Farmington, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Moebius","sequence":"additional","affiliation":[{"name":"FORUM Pharmaceuticals Incorporated, Waltham, Massachusetts"},{"name":"Athira Pharma Inc, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L.","family":"Boxer","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, Department of Neurology, University of California at San Francisco, Weill Institute for Neurosciences, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,9,24]]},"reference":[{"issue":"4","key":"zoi210757r1","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.trci.2017.08.002","article-title":"An 8-week, open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations.","volume":"3","author":"Sha","year":"2017","journal-title":"Alzheimers Dement (N Y)"},{"issue":"7105","key":"zoi210757r7","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/nature05016","article-title":"Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17.","volume":"442","author":"Baker","year":"2006","journal-title":"Nature"},{"issue":"20","key":"zoi210757r8","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1093\/hmg\/ddl241","article-title":"Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration.","volume":"15","author":"Gass","year":"2006","journal-title":"Hum Mol Genet"},{"issue":"3","key":"zoi210757r9","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1074\/jbc.M705115200","article-title":"Missense mutations in the progranulin gene linked to frontotemporal lobar degeneration with ubiquitin-immunoreactive inclusions reduce progranulin production and secretion.","volume":"283","author":"Shankaran","year":"2008","journal-title":"J Biol Chem"},{"issue":"6","key":"zoi210757r10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrn.2017.36","article-title":"Progranulin, lysosomal regulation and neurodegenerative disease.","volume":"18","author":"Kao","year":"2017","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"zoi210757r11","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1159\/000447738","article-title":"Progranulin levels in plasma and cerebrospinal fluid in granulin mutation carriers.","volume":"6","author":"Meeter","year":"2016","journal-title":"Dement Geriatr Cogn Dis Extra"},{"issue":"pt 3","key":"zoi210757r12","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/brain\/awn352","article-title":"Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members.","volume":"132","author":"Finch","year":"2009","journal-title":"Brain"},{"issue":"18","key":"zoi210757r15","doi-asserted-by":"publisher","first-page":"16101","DOI":"10.1074\/jbc.M110.193433","article-title":"Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia.","volume":"286","author":"Cenik","year":"2011","journal-title":"J Biol Chem"},{"issue":"3","key":"zoi210757r16","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.euroneuro.2014.12.007","article-title":"Increasing progranulin levels and blockade of the ERK1\/2 pathway: upstream and downstream strategies for the treatment of progranulin deficient frontotemporal dementia.","volume":"25","author":"Alquezar","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"zoi210757r17","doi-asserted-by":"publisher","first-page":"419","DOI":"10.4103\/0019-5154.160511","article-title":"Vorinostat-an overview.","volume":"60","author":"Bubna","year":"2015","journal-title":"Indian J Dermatol"},{"key":"zoi210757r18","author":"Hanson","year":"2013"},{"issue":"pt 11","key":"zoi210757r19","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1093\/brain\/awn234","article-title":"Development of methodology for conducting clinical trials in frontotemporal lobar degeneration.","volume":"131","author":"Knopman","year":"2008","journal-title":"Brain"},{"issue":"1","key":"zoi210757r20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jalz.2019.05.013","article-title":"Use of the CDR\u00ae plus NACC FTLD in mild FTLD: data from the ARTFL\/LEFFTDS consortium.","volume":"16","author":"Miyagawa","year":"2020","journal-title":"Alzheimers Dement"},{"issue":"1","key":"zoi210757r21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4103\/2229-3485.173781","article-title":"Interactive voice\/web response system in clinical research.","volume":"7","author":"Ruikar","year":"2016","journal-title":"Perspect Clin Res"},{"issue":"12","key":"zoi210757r23","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"7","key":"zoi210757r24","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice.","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"issue":"20","key":"zoi210757r25","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1212\/WNL.0b013e3181e04070","article-title":"Clinical staging and disease progression in frontotemporal dementia.","volume":"74","author":"Mioshi","year":"2010","journal-title":"Neurology"},{"key":"zoi210757r27","author":"Xia","year":"2013"},{"issue":"6","key":"zoi210757r29","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1210\/endo.133.6.8243292","article-title":"The complementary deoxyribonucleic acid sequence, tissue distribution, and cellular localization of the rat granulin precursor.","volume":"133","author":"Bhandari","year":"1993","journal-title":"Endocrinology"},{"issue":"15","key":"zoi210757r30","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1212\/WNL.0b013e3182a8237e","article-title":"Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers.","volume":"81","author":"Jacova","year":"2013","journal-title":"Neurology"},{"issue":"11","key":"zoi210757r31","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1212\/01.wnl.0000254460.31273.2d","article-title":"Clinicopathologic features of frontotemporal dementia with progranulin sequence variation.","volume":"68","author":"Spina","year":"2007","journal-title":"Neurology"},{"issue":"1-2","key":"zoi210757r32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jns.2005.03.015","article-title":"Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss.","volume":"233","author":"Petzold","year":"2005","journal-title":"J Neurol Sci"},{"issue":"1","key":"zoi210757r33","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/ana.24052","article-title":"Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration.","volume":"75","author":"Scherling","year":"2014","journal-title":"Ann Neurol"},{"issue":"10","key":"zoi210757r34","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1002\/acn3.2018.5.issue-10","article-title":"Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory.","volume":"5","author":"Ljubenkov","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"issue":"8","key":"zoi210757r35","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/acn3.325","article-title":"Neurofilament light chain: a biomarker for genetic frontotemporal dementia.","volume":"3","author":"Meeter","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"issue":"6","key":"zoi210757r36","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cmet.2011.08.016","article-title":"Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation.","volume":"14","author":"B\u00e9langer","year":"2011","journal-title":"Cell Metab"},{"issue":"4","key":"zoi210757r37","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3233\/JAD-2011-111046","article-title":"Cerebrospinal fluid biomarkers in Progranulin mutations carriers.","volume":"27","author":"Carecchio","year":"2011","journal-title":"J Alzheimers Dis"},{"issue":"9","key":"zoi210757r38","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1084\/jem.20160999","article-title":"Progranulin deficiency causes impairment of autophagy and TDP-43 accumulation.","volume":"214","author":"Chang","year":"2017","journal-title":"J Exp Med"},{"key":"zoi210757r39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.pneurobio.2013.03.001","article-title":"Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system.","volume":"105","author":"Lee","year":"2013","journal-title":"Prog Neurobiol"},{"key":"zoi210757r14","author":"Patzke"},{"key":"zoi210757r40","author":"Paul"},{"key":"zoi210757r41","author":"Paul"},{"key":"zoi210757r2","unstructured":"Alector. Our science. Accessed June 20, 2020. https:\/\/alector.com\/our-science\/"},{"key":"zoi210757r3","unstructured":"Prevail. Our pipeline. Accessed February 17, 2020. https:\/\/www.prevailtherapeutics.com\/programs\/"},{"key":"zoi210757r4","unstructured":"Arkuda Therapeutics. Discovery. Accessed June 20, 2020. https:\/\/www.arkudatx.com\/discovery\/"},{"key":"zoi210757r5","unstructured":"Passage Bio. Pipeline. Accessed June 20, 2020. https:\/\/www.passagebio.com\/our-science\/pipeline\/"},{"key":"zoi210757r6","unstructured":"Denali. Our pipeline. Accessed June 20, 2020. https:\/\/denalitherapeutics.com\/pipeline"},{"key":"zoi210757r13","unstructured":"A phase 3 study to evaluate efficacy and safety of AL001 in frontotemporal dementia (INFRONT-3). Clinicaltrials.gov identifier: NCT04374136. Accessed August 21, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04374136?term=NCT04374136&draw=2&rank=1"},{"key":"zoi210757r22","unstructured":"Alzheimer\u2019s Disease Neuroimaging Initiative. Study documents. Accessed May 13, 2021. http:\/\/adni.loni.usc.edu\/methods\/documents\/"},{"key":"zoi210757r26","unstructured":"Stata.com. Pharmacokinetic (biopharmaceutical) data. Accessed June 13, 2020. https:\/\/www.stata.com\/manuals13\/rpk.pdf"},{"key":"zoi210757r28","unstructured":"Neuromorphometrics, Inc. Modeling the living human brain. Accessed May 13, 2021. http:\/\/www.neuromorphometrics.com"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2784478\/ljubenkov_2021_oi_210757_1631885845.47256.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T15:39:34Z","timestamp":1632497974000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2784478"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2021,9,24]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.25584","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,24]]}}}